CergenX is an AI-driven neurotechnology company transforming early brain health with AI-powered clinical insights. Combining decades of world-leading neonatal brain research and the latest advances in AI, CergenX is working to transform the early detection and management of newborn brain injury to improve outcomes globally.

The company’s first product, Wave, is an FDA-designated breakthrough device designed to rapidly screen newborns at risk of brain injury. Wave’s 10-minute assessment is the first AI-powered device to deliver an advanced neurological assessment without requiring specialist expertise, enabling earlier and more consistent identification of newborns at risk of neonatal encephalopathy. Backed by FDA Breakthrough Device Designation, robust clinical evidence, and state-of-the-art AI performance, CergenX is positioned to redefine the standard of neonatal brain care worldwide.

Beneath Wave, CergenX’s enterprise-grade AI platform, provides the foundation to rapidly expand its pipeline across neurological conditions and diverse physiological data streams. By unlocking the clinical utility of established time-series diagnostics, the platform transforms complex biosignals into powerful, actionable assessments for healthcare providers.